Welcome to our dedicated page for VivoSim Labs SEC filings (Ticker: VIVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VivoSim Labs, Inc. (VIVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed pharmaceutical and biotechnology services company, VivoSim Labs uses these filings to report on corporate governance, executive compensation, auditor ratification, board elections and other matters relevant to stockholders.
Core documents include annual proxy statements on Schedule 14A, where the company outlines items such as the election of directors, the ratification of its independent registered public accounting firm, advisory votes on executive compensation and the frequency of say‑on‑pay votes. These materials also summarize aspects of VivoSim Labs’ governance framework, including board composition, independence, committee structure and compensation practices.
Current reports on Form 8‑K provide timely disclosure of specific events, such as the appointment of key executives. For example, VivoSim Labs has filed an 8‑K describing the appointment of a Chief Commercial Officer, including information about the role, background and related compensatory arrangements. Another 8‑K reports the results of the company’s annual meeting of stockholders, detailing vote counts for director elections, auditor ratification and advisory proposals.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the outcomes of stockholder votes, changes in leadership roles and the structure of executive compensation without reading every page of the underlying filing. The page also surfaces Forms 10‑K and 10‑Q when available, along with Forms 4 and other ownership reports, enabling investors to review periodic reporting and insider transaction disclosures with AI‑generated highlights and context.
VivoSim Labs, INC. (VIVS) reported that its Chief Commercial Officer, Lialin Tony Serge, purchased 10,000 shares of common stock on 2026-08-31 at an average price of $0.2804 per share in an open-market or private transaction. Following this trade, he held 10,000 shares directly, and the filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
VivoSim Labs, Inc. (VIVS) reports that Nasdaq has notified the company that its common stock no longer satisfies Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share based on the closing bid price over the last 30 consecutive business days.
Under Nasdaq Listing Rule 5810(c)(3)(A), VivoSim has 180 calendar days, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for 10 consecutive business days. The company may qualify for an additional 180‑day compliance period if it meets other Nasdaq Capital Market initial listing standards (aside from bid price) and notifies Nasdaq of its intent to cure the deficiency. The notice has no immediate effect on trading, and VIVS will continue to trade on the Nasdaq Capital Market. VivoSim is monitoring its stock price and is seeking stockholder approval for a reverse stock split in a range of 1‑for‑5 to 1‑for‑20, which it believes could help regain compliance, though there is no assurance the split will be approved, implemented, or successful, or that other Nasdaq listing requirements will continue to be met.
VivoSim Labs, Inc. (VIVS) is asking stockholders to vote at a fully virtual annual meeting on September 30, 2026. As of August 13, 2026, the company had 16,586,495 common shares outstanding, its only voting class. Six proposals are up for vote, including electing two Class III directors, ratifying the auditor, an advisory Say‑on‑Pay vote, authorizing a reverse stock split within a 1‑for‑5 to 1‑for‑20 range without reducing authorized shares, a major expansion of the 2022 Equity Incentive Plan, and approval of warrant share issuance and repricing tied to a July 2026 private placement. The equity plan amendment would add 3,165,000 shares for awards, and Proposal 6 would permit issuance of 4,705,883 common shares on warrant exercise and cut the exercise price of May 13, 2024 Investor Warrants from $9.60 to $0.85 per share. The board unanimously recommends voting FOR all proposals and highlights a five‑member board with four independent directors and various governance and compensation "best practice" policies.
VivoSim Labs, Inc. received an amended Schedule 13G reporting that Esousa Group Holdings LLC and Michael Wachs together beneficially own 319,429 shares of common stock, representing 9.9% of the outstanding common stock. This ownership is based on 3,194,295 shares outstanding as of June 30, 2026.
The reporting persons also hold warrants for 576,542 additional shares, but these are excluded from beneficial ownership because a Beneficial Ownership Limitation in the warrants prevents exercises that would raise their ownership above 9.9%. They report sole voting and dispositive power over the 319,429 shares and no shared power.
VivoSim Labs, Inc. is asking stockholders to approve several governance and capital-structure actions at its fully virtual 2026 Annual Meeting on September 30, 2026 at 9:00 a.m. Pacific. Stockholders of record on August 13, 2026, when 16,586,495 common shares were outstanding, may vote online, by phone, or mail.
Key items include electing two Class III directors, ratifying Rosenberg Rich Baker Berman P.A. as auditor for fiscal year ending March 31, 2027, an advisory “Say-on-Pay” vote, and a proposal authorizing a reverse stock split at a Board-selected ratio between 1-for-5 and 1-for-20 without reducing authorized common shares. The company also seeks to amend and restate its 2022 Equity Incentive Plan to increase the share reserve (amount to be finalized) and to approve, under Nasdaq rules, the issuance of 4,705,883 common shares upon warrant exercise and a reduction of the exercise price on certain 2024 investor warrants from $9.60 to $0.85 per share. The Board highlights a five‑member Board with four independent directors, formal governance guidelines, and multiple compensation “best practices,” and recommends voting FOR all proposals.
VivoSim Labs, Inc. reported a small revenue base and ongoing losses while strengthening liquidity after quarter‑end. For the quarter ended June 30, 2026, royalty revenue was $18,000 versus $37,000 a year earlier, reflecting dependence on a single IP licensing customer. Research and development expense was $1.1 million and selling, general and administrative expense was $1.6 million, leading to an operating loss of $2.8 million. A $1.4 million gain from remeasuring common stock warrant liabilities reduced the net loss to $1.3 million, compared with a $2.8 million net loss in the prior‑year period.
At June 30, 2026, cash and cash equivalents were $1.7 million with total assets of $3.8 million, liabilities of $6.2 million, and a stockholders’ deficit of $2.3 million. Operating cash outflow was $3.2 million for the quarter, and management expects fiscal 2027 operating expense of $10.7 million. The company states that these factors and its accumulated deficit of $357.3 million raise substantial doubt about its ability to continue as a going concern without additional financing. Subsequent to quarter‑end, VivoSim received $6.0 million tied to the FXR314 asset sale and completed a $4.0 million private placement, and all 3,947,369 2026 Common Warrants were exercised, eliminating the related $4.3 million warrant liability.
VivoSim Labs, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on September 30, 2026. Holders of common stock at the August 13, 2026 record date may vote online, by phone, by mail, or during the webcast at www.virtualshareholdermeeting.com/VIVS2026.
Key items include electing two Class III directors (Keith Murphy and Adam Stern) to terms through the 2029 meeting, ratifying Rosenberg Rich Baker Berman P.A. as auditor for the year ending March 31, 2027, and an advisory "Say‑on‑Pay" vote on named executive officer compensation. Stockholders are also asked to approve a board‑discretionary reverse stock split within a ratio range to be selected by the board any time on or before September 30, 2027, without reducing the 200,000,000 authorized common shares and with cash paid in lieu of fractional shares.
Additional proposals seek to amend and restate the 2022 Equity Incentive Plan to increase the share reserve, and to approve under Nasdaq Listing Rule 5635(d) the issuance of up to 4,705,883 common shares upon exercise of July 2026 private‑placement warrants and a reduction in the exercise price of May 13, 2024 investor warrants from $9.60 to $0.85 per share. The company highlights a five‑member board with four independent directors and various governance and compensation practices, including stock ownership guidelines, independent board committees, and prohibitions on hedging and pledging.
VivoSim Labs, Inc. reported that the Nasdaq Listing Qualifications Staff has determined the company now complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. After filing its Form 10-K for the year ended March 31, 2026, VivoSim received a $5.0 million milestone payment and a further $1.0 million escrow release from Eli Lilly related to a prior FXR program sale, and completed a July 17, 2026 financing issuing pre-funded and common warrants at $0.85 per underlying share for $4.0 million in gross proceeds.
These July events are not reflected in previously filed annual or upcoming quarterly financial statements. As of August 3, 2026, cash on hand was approximately $10.1 million. Common shares outstanding increased from 3,194,295 on June 30, 2026 to 13,390,789 on August 3, 2026, driven by warrant exercises. VivoSim reiterated guidance that it anticipates 500%+ revenue growth in Fiscal Year 2027 as it expands contract research services using its NAM 3D human tissue models for pharmaceutical customers.